AGEN logo

AGENUS INC

AGENNASDAQ
πŸ† #3252 by market capEarnings Mar 15US Equity
β€”β€”
Quote unavailable
πŸ””
Track AGEN
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$270M
Small Cap
πŸ“ˆRevenue Growth (YoY)
30.5%
High Growth
πŸ“ŠGross Margin
99.5%
High
πŸ’΅FCF Margin
82.1%
Strong
βš–οΈP/S Ratio
2.0x
Cheap
Otter Score
β€”
Insufficient data
No chart data available for AGEN.

Trading Snapshot

Day Range
β€”
52-Week Range
$2.71 – $10.31
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
45.0M
Next Earnings
2027-03-15

Fundamentals Snapshot

Annual Revenue
$114M
Last Q Revenue
$31M
P/E Ratio
2.9
P/S Ratio
2.0x
EPS (TTM)
$2.65
Dividend Yield
β€”
Dilution (1yr)
+38.5%
AGEN logo

AGENUS INC

AGEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$114Mβ–² +10.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
29.6%β–Ό βˆ’158.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$21Mβ–Ό βˆ’82.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$159Mβ–² +0.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
29.7Mβ–² +38.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$332Mβ–Ό βˆ’$277M YoY
StockOtter Β· stockotter.space

About AGENUS INC

Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company's innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

Seeking AlphaΒ·16d ago

Agenus Inc. (AGEN) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial Transcript

Agenus Inc. ( AGEN ) Discusses BOT BAL Development and Planned Phase 3 ROBBIN Trial November 5, 2026 11:30 AM EST Company Participants Zack Armen - Vice President of Investor Relations & Corporate Development Robin Taylo

Zacks Investment ResearchΒ·16d ago

Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock Down

AGEN's Q3 earnings meet estimates, but a revenue miss weighs on shares as pipeline progress, Armenian drug approvals and new funding emerge as key developments.

Business WireΒ·16d ago

Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Botensilimab--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new findings from a long-term survivor analysis of its Phase 1b C-800-01 tria

MarketBeatΒ·17d ago

Agenus Targets Phase 3 Colon Cancer Trial as Financing Hinges on Enrollment Milestones

Agenus NASDAQ: AGEN expects to begin enrolling patients in the next few months for a Phase 3 trial of its investigational immunotherapy combination BOT/BAL in early-stage colon cancer, executives said during an investor

Business WireΒ·17d ago

Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #Armenia--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today reported financial results for the third quarter ended September 30, 2026, and highlighted p

Business WireΒ·20d ago

Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat

LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #IO--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Chief Commercial Officer, and Zack Armen, Vice President of Corporat